Attorney's Docket No.: 20381-003US1 / PCT04TL2

Applicant: Kenichiro Kosai et al. Serial No.: To Be Assigned

Filed : Herewith Page : 3 of 7

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (Original) A drug for preventing or treating a heart disease, comprising an expression vector containing a CD9 gene as the active ingredient.
- 2. (Original) The drug for preventing or treating a heart disease according to Claim 1, wherein the heart disease is a disease causative of heart failure.
- 3. (Original) The drug for preventing or treating a heart disease according to Claim 1, wherein the heart disease is a ischemic heart disease.
- 4. (Original) The drug for preventing or treating a heart disease according to Claim 3, wherein the ischemic heart disease is myocardial infarction.
- 5. (Original) The drug for preventing or treating a heart disease according to Claim 1, wherein the heart disease includes one or more of cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases and myocarditis.
- 6. (Original) The drug for preventing or treating a heart disease according to Claim 1, wherein the heart disease is arrhythmia.
- 7. (Original) The drug for preventing or treating a heart disease according to Claim 6, wherein the arrhythmia is tachyarrhythmia.
- 8. (Original) The drug for preventing or treating a heart disease according to Claim 7, wherein the tachyarrhythmia is superventricular arrhythmia and/or ventricular arrhythmia.
- 9. (Currently Amended) The drug for preventing or treating a heart disease according to any of Claims 6 to 8 Claim 6, wherein the heart disease is one or more of WPW syndrome, long

Attorney's Docket No.: 20381-003US1 / PCT04TL2

Applicant: Kenichiro Kosai et al. Serial No.: To Be Assigned

Filed : Herewith Page : 4 of 7

6

QT syndrome, Brugada syndrome, and arrhythmia-inducing right ventricular dysplasia (ARVD, ARVC).

- 10. (Original) The drug for preventing or treating a heart disease according to Claim 1, wherein the heart disease is associated with cardiac hypertrophy and/or tachycardia.
- 11. (Original) The drug for preventing or treating a heart disease according to Claim 10, wherein cardiac hypertrophy or tachycardia is caused by at least one of HB-EGF (heparin binding epidermal growth factor), HGF (hepatocyte growth factor) or angiotensin 2.
- 12. (Currently Amended) The drug for preventing or treating a heart disease according to any of Claims 1 to 11 Claim 1, wherein the expression vector is a viral vector or a non-viral vector.
- 13. (Original) The drug for preventing or treating a heart disease according to Claim 12, wherein the viral vector is adenovirus, adeno-associated virus, retrovirus, herpesvirus, herpes simplex virus, lentivirus, Sendai virus, poxvirus, poliovirus, symbis virus or vaccinia virus.
- 14. (Original) A method for preventing or treating a heart disease, comprising expressing a CD9 gene in heart.
- 15. (Original) The method for preventing or treating a heart disease according to Claim 14, wherein the heart disease is a disease causative of heart failure.
- 16. (Original) The method for preventing or treating a heart disease according to Claim 14, wherein the heart disease is a ischemic heart disease.
- 17. (Original) The method for preventing or treating a heart disease according to Claim 16, wherein the ischemic heart disease is myocardial infarction.

Applicant: Kenichiro Kosai et al. Attorney's Docket No.: 20381-003US1 / PCT04TL2

Serial No.: To Be Assigned

Filed : Herewith Page : 5 of 7

18. (Original) The method for preventing or treating a heart disease according to Claim 14, wherein the heart disease includes one or more of cardiomyopathy, hypertensive heart diseases, valvular disease, congenital heart diseases and myocarditis.

- 19. (Original) The method for preventing or treating a heart disease according to Claim 14, wherein the heart disease is arrhythmia.
- 20. The method for preventing or treating a heart disease according to Claim 19, wherein the arrhythmia is tachyarrhythmia.
- 21. (Original) The method for preventing or treating a heart disease according to Claim 20, wherein the tachyarrhythmia is superventricular arrhythmia and/or ventricular arrhythmia.
- 22. (Currently Amended) The method for preventing or treating a heart disease according to any of Claims 19 to 21 Claim 19, wherein the heart disease is one or more of WPW syndrome, long QT syndrome, Brugada syndrome, arrhythmia-inducing right ventricular dysplasia (ARVD, ARVC).
- 23. (Original) The method for preventing or treating a heart disease according to Claim 14, wherein the heart disease is associated with cardiac hypertrophy and/or tachycardia.
- 24. (Original) The method for preventing or treating a heart disease according to Claim 23, wherein cardiac hypertrophy or tachycardia is caused by at least one of HB-EGF (heparin binding epidermal growth factor), HGF (hepatocyte growth factor) or angiotensin 2.
- 25. (Currently Amended) The method for preventing or treating a heart disease according to any of Claims 14 to 24 Claim 14, wherein the prevention or treatment is carried out by a gene therapy of transferring a CD9 gene.

Applicant: Kenichiro Kosai et al. Attorney's Docket No.: 20381-003US1 / PCT04TL2

Serial No.: To Be Assigned

Filed : Herewith Page : 6 of 7

26. (Original) The method for preventing or treating a heart disease according to Claim 25, wherein the gene therapy comprises using a drug containing an expression vector containing a CD9 gene as the active ingredient.

27. (Currently Amended) The method for preventing or treating a heart disease according to any of claims 14 to 24 Claim 14, wherein the prevention or treatment comprises administration of an expression inducing substance for expressing endogenous cd9.